Google Invests In Genetic Indexing

Bibek Paudel point us to a BusinessWeek report on Google's interest in the cataloging and analyzing of people's DNA. Google has recently invested in DNA screening firms Navigenics and 23andMe, which test customers' DNA for characteristics such as ancestry and predisposition for certain diseases. The customers are then able to give the information to their doctors. This is not Google's first foray into the medical industry. "Google wants to plant an early stake in a potentially large new market around genetic data. 'We are interested in supporting companies and making investments in companies that [bolster] our mission statement, which is organizing the world's information and making it universally accessible and useful,' Google spokesman Andrew Pederson says. 'We felt it was important to get involved now, at the early stage, to better understand the information generated by this fast-moving field.'"

Comments

Be afraid, be very afraid....

[ColdWetDog]

All your base (pairs) belong to us!

I'm just dying to know

[way2trivial]

what kinds of adsense relationships they can match to genetic markers.

the mind boggles....

marker for a small penis and low intelligence? show them a camarro
small penis and high intelligence? corvette

Re:I'm just dying to know

[FooAtWFU]

Your (small) mind may boggle, but really, a) it's not about AdSense, it's about being a major player in the medical industry (where you get paid by hospitals and insurance companies and what-have-you, not just advertisements), and b) even if it was, if you had (say) a propensity for heart disease, one could see ads for all those "heart healthy" oatmeal+etc things.

Re:I'm just dying to know

[ColdWetDog]

it's about being a major player in the medical industry

I think this is it. The Next Big Thing in the Medical Industrial Complex (other than taking out all of the insurance company executives and shooting them) is going to be managing enormous amounts of data. The Industry has shown it can't do it: Insurance companies have a vested interest in NOT letting anyone else see what they are doing / what data they're finding. The government - Bush's weak pronouncements aside - won't do anything. The various private companies involved in Health Care computing are still too small and fragmented to get anything done on a major scale within the mess that is the current US Healthcare system.

This means either medical information will remain balkanized for the foreseeable future (which isn't necessarily a bad thing), or somebody (ie. Google and / or Microsoft) is going to try to tie everything together. Of course, this won't fix the major issues in healthcare delivery and financing in the US but it's one piece of the puzzle.

I read about this in Wired

[Cytlid]

Here's the link:

http://www.wired.com/medtech/genetics/magazine/15-12/ff_genomics

I thought it was interesting then. It's also important to point out, Anne Wojcicki's husband's name is Sergey Brin. Having access to massive amounts of computing power makes sense for a genetics company.

Insurance implications?

[nathan_w_cheng]

I recently attended a legal studies lecture in which the professor (a lawyer) asserted that if any of us were to participate in such a program and any disease or predisposition for disease were discovered, that we would be legally obligated to make this known to any potential medical insurers the next time we apply for medical insurance. According to this lawyer, failure to disclose in this manner would result in annulment of the insurance should the failure be discovered.

universally accessible and useful

[delvsional]

What if I don't want my medical data to to "universally accessible"?

Google DNA Mashups!

[KnowledgeEngine]

New from Google for 2009 DNA Mashups!

Just login, choose your favorite DNA Samples (or upload your own), and select the chromosone pairs from the samples you wish to combine!
Next choose Preview to see what your new organism will look like! Also, upload a base sample for a comparison chart between the original organism and your new lifeform!

Last but not least our engineers hope to have a special suprise ready by April of 2010. Ordering! We hope to offer both "Retrovirus" for exisiting organism modification, and "Test Tube Compatible" for creating new lifeforms!

Warning: Google claims no responsiblity for lifeforms based on DNA created with the beta.

Direct to consumer genetic testing

[chooks]

The New England Journal of Medicine actually had an interesting article about direct-to-consumer genetic testing (Jan 10, 2008 -- sorry not a free link (unless you can get it through your institution)). Three main points it makes is that

1. There are questions regarding quality control and transparency. Due to the numbers involved, even small percentage mistakes in sequencing can add up and give wrong information.
2. What is the clinical validity of the sequence such that it can accurately predict the disease? Lack of a sequence may give a false sense of security, and presence of a sequence may cause unnecessary harm.
3. What can you do clinically given the answers? There is little observational or clinical data for how the genetic information can be used effectively, especially for low penetrant conditions.

Clearly, there are disease where knowing ones gene status is very helpful (e.g. BRCA1/2, MEN1/2A/2B, etc...) but many disease we are just in the infancy of determining their genetic basis. The article sums things up like this:

So what advice should a physician offer patients? For the patient who appears with a genome map and printouts of risk estimates in hand, a general statement about the poor sensitivity and positive predictive value of such results is appropriate, but a detailed consumer report may be beyond most physicians' skill sets. For the patient asking whether these services provide information that is useful for disease avoidance, the prudent answer is "Not now -- ask again in a few years." More information is needed on the clinical utility of this information in the light of existing disease-specific opportunities for prevention or early detection and the potential value that genomic profiles can add to that of simpler tools, such as the family health history. Finally, given the risk of commercial exploitation, if patients are determined to proceed, perhaps because they are simply curious, are genetic hobbyists, or are "early adopters" of new technology, it would make sense to encourage them to enroll in formal scientific studies.